Subject:
- Active Sustance: Pembrolizumab
- Name: Keytruda®
- Therapeutic area: Renal cell carcinoma
- Pharmaceutical company: MSD Sharp & Dohme GmbH
Time table:
- Start: 01.08.2022
- Final decision by G-BA: 19.01.2023
Final decision:
- Hint for a minor additional benefit